Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCOLYTIC-HERPES

Financiado

Cerrado

ONCOLYTIC HERPESVIRUSES RETARGETED TO CANCER SPECIFIC RECEPTORS

Cancer remains a major health burden worldwide. The aggressive targeting of metabolic pathways shared by normal and cancer cells results in prolonged survival and cures, but at a tremendous cost to patient life quality. What is mi... ver más

29/02/2020

UNIBO

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2020-02-29 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNIBO

0.00€ | Lider

UNIGE

N.D. | Participante

UNIVR

N.D. | Participante

Proyectos interesantes

AVITAG

Medical Technol...

Applied Physics

186K€ Cerrado

BFU2017-84762-R

Medical Technol...

Applied Physics

330K€ Cerrado

SAF2008-03238

Medical Technol...

Genetic Enginee...

121K€ Cerrado

BIO2017-89754-C2-2-R

Medical Technol...

Biotechnology

242K€ Cerrado

Syst-Onco-Herpes

Medical Technol...

Biotechnology

150K€ Cerrado

BIO2008-04692-C03-01

Medical Technol...

Biotechnology

151K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer remains a major health burden worldwide. The aggressive targeting of metabolic pathways shared by normal and cancer cells results in prolonged survival and cures, but at a tremendous cost to patient life quality. What is missing is a therapeutic agent that clearly differentiates normal and cancer cells. This proposal delineates a process for killing exclusively cancer cells with no interference with normal cells. In the past two decades there has been considerable effort to develop attenuated viruses for killing cancer cells. Of the oncolytic viruses in clinical trials, attenuated herpes simplex viruses (HSV) are among the most promising because of safety, affinity for cancer cells, ability to treat patients multiple times without block by adaptive immunity. The shortcoming is that they do not discriminate between normal and cancer cells, are effective in a limited number of patients. The remarkable accomplishment by my laboratory at the basis of the proposal is the genetic engineering of HSVs that specifically infect and kill cancer cells and cannot infect normal cells. The prototype retargeted HSV targets HER2, a receptor in breast, ovary and other tumors. HER2-HSV ablates human breast and ovary cancers, and glioblastoma after intratumoral or intraperitoneal administration. This proposal addresses basic research issues for the advancement of retargeted oncolytic HSVs. It is organized in 5 AIMS • Engineer a non-cancer cell line for virus production acceptable to Health Authorities and re-engineer the retargeted-HSV accordingly. This will enable production of clinical grade retargeted-HSVs for clinical tests (AIM1) • Engineer retargeted-HSVs suitable for systemic delivery and for boosting anti-tumor immunity (AIM2-3) • Apply our platform to expand the repertoire of oncolytic HSVs that target glioblastomas, prostate, head-and-neck, colon carcinomas (AIM4) • Determine the tumorigenic potential of cancer cells that escape killing by retargeted HSVs (AIM5)

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores